Thales High Tech to Offer Thai Citizens One of the World’s Most Secure E-Passports
Even though the COVID-19 health crisis has been severely disrupting the global travel industry, in the past few months the DGM Consortium has continued its close collaboration with MOFA. Global teams were working remotely to deliver the project, supporting the Thai Government’s ‘Thailand 4.0’ vision to develop an innovative, digital economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005034/en/
Thai passports (Photo: Thales)
The new Thai e-passport project was delivered on the 8th of July to MOFA and launched in an official inauguration ceremony conducted on the 5th of August in the presence of Minister Don Pramudwinai, Minister of Foreign Affairs of Thailand.
The Thai e-passport project is one of the largest passport programs for Thales worldwide, as it aims to provide Thai citizens superior technology and the highest possible level of security in a travel document.
The newly designed 64-page biometric travel document includes an e-Cover and a thin, flexible data page made of polycarbonate material. The reverse side of the data page features a high definition, true color UV picture of one of Bangkok’s most iconic landmarks, the Wat Arun temple. The security features visible on the data page include an additional secondary image of the citizen perforated in the semi-transparent window; as well as the traditional Thai four-petal lotus symbol, the line-pra-jum-yam, embossed using Thales’ Secure Surface technology.
Designed to counter new types of forgeries, Thales Secure Surface provides optical elements with light reflective and animation effects revealed by tilting a document in different angles. This visible security feature allows fast and efficient verification by border authorities.
An additional perceptible feature is the tactile signature of the citizen embossed on the data page. Biometric data is securely embedded into the passport chip using Thales’ secure embedded software. This software provides strong security for identification and protection of citizens’ privacy.
The technological features of the passport ensures secure and fast border crossing, while complying with all relevant data protection laws in Thailand and is fully compliant to the highest security standards recommended by the International Civil Aviation Organisation (ICAO).
Since the project’s inception, Thales has trained 250 local experts in its passport issuance technologies. Over the next seven years, Thales will be operating know-how transfer and upskilling more than 500 Thai nationals in its technologies, thus significantly contributing to the local economy.
Thales has been a dedicated partner to Thailand for almost 50 years in industry sectors ranging from defence to air traffic management and ground transportation. Aligning with this vision Thales will henceforth be providing its digital identity and biometrics expertise to the Thai Ministry of Foreign Affairs, making the Group their trusted partner as they deliver a highly-secure and modern passport for their citizens.
“I am delighted that Thales has successfully delivered this new generation passport to Thai citizens and helped the Ministry of Foreign Affairs (MOFA) strengthen homeland protection and safeguard their citizens’ identities. Throughout the last few months amidst the global COVID-19 pandemic, we have continued our close collaboration with MOFA and worked tirelessly to deliver this milestone. Thai citizens now possess one of the world’s most sophisticated e-passports that integrate biometrics and other high-security features that will provide a seamless and secure travel experience. We will continue to build local expertise in passport issuance with training and transfer-of-technology aligned with our commitment to upskilling the Thai workforce as Thailand moves towards a digital future.” Massimo Marinzi, Country Director, Thales in Thailand
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005034/en/
Contact information
Thales, Media relations
Digital Identity & Security
Vanessa Viala
+33 (0) 6 89 73 25 47
vanessa.viala@thalesgroup.com
Thales, South East Asia Communications
Serene Koh
+65 6594 6898
serene.koh@asia.thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom